(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -18.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Arrowhead Pharmaceuticals's revenue in 2026 is $829,448,000.On average, 15 Wall Street analysts forecast ARWR's revenue for 2026 to be $55,721,303,552, with the lowest ARWR revenue forecast at $13,309,336,684, and the highest ARWR revenue forecast at $85,497,549,143. On average, 13 Wall Street analysts forecast ARWR's revenue for 2027 to be $37,643,693,286, with the lowest ARWR revenue forecast at $18,460,593,219, and the highest ARWR revenue forecast at $57,169,033,440.
In 2028, ARWR is forecast to generate $68,851,371,619 in revenue, with the lowest revenue forecast at $42,589,877,389 and the highest revenue forecast at $102,016,065,683.